Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Oligodendroglioma 2Melanoma 2Leukemia, Myeloid, Acute 2Gliosarcoma 2Glioblastoma 2Central Nervous System Neoplasms 2Brain Neoplasms 2Astrocytoma 2Sarcoma, Kaposi 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hodgkin Disease 1Histiocytosis 1Hemoglobinuria, Paroxysmal 1Hemoglobinuria 1Hematologic Neoplasms 1HIV Infections 1Glioma, Subependymal 1Glioma 1Anemia, Refractory, with Excess of Blasts 1Acquired Immunodeficiency Syndrome 1

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Melanoma × Muromonab-CD3 × Clear all
NCT00004022 2013-04-05

Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
Dermatologic

Melanoma

NCT00080353 2012-06-14

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
58 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡